Preclinical Evidence That Trametinib Enhances the Response to Tyrosine Kinase Inhibitors in Acute Myeloid Leukemia

被引：1
|
作者：
Martinez-Lopez, Joaquin [1 ]
Linares, Maria [2 ]
Morales, Maria Luz [2 ]
Arenas, Alicia [1 ]
Zagorac, Ivana [3 ]
Ayala, Rosa M. [1 ]
Castro, Nerea [4 ]
Rapado, Inmaculada [5 ]
Quintela-Fandino, Miguel [3 ]
机构：
[1] Octubre Hosp, Dept Hematol, Madrid, Spain
[2] Hosp 12 Octubre, Inst Invest, Madrid, Spain
[3] Ctr Nacl Invest Oncol, Madrid, Spain
[4] Hosp Octubre, Ser Hematol, Madrid, Spain
[5] Hosp Univ 12 Octubre, Madrid, Spain
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.1581.1581
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1581
引用
收藏
页数：4
相关论文
共 50 条
  • [1] PRECLINICAL EVIDENCE THAT TRAMETINIB ENHANCES THE RESPONSE TO TYROSINE KINASE INHIBITORS IN ACUTE MYELOID LEUKEMIA
    Morales, M. L.
    Linares, M.
    Arenas, A.
    Zagorac, I.
    Ayala, R.
    Castro, N.
    Rapado, I.
    Quintela-Fandino, M.
    Martinez-Lopez, J.
    HAEMATOLOGICA, 2017, 102 : 369 - 369
  • [2] TRAMETINIB PROMOTES RESPONSE TO TYROSINE KINASE INHIBITORS IN ACUTE MYELOID LEUKEMIA
    Morales, M. L.
    Linares, M.
    Arenas, A.
    Leivas, A.
    Zagorac, I
    Ayala, R.
    Castro, N.
    Rapado, I
    Gomez, G.
    Quintela Fandino, M.
    Martinez Lopez, J.
    HAEMATOLOGICA, 2017, 102 : 79 - 80
  • [3] TRAMETINIB ENHANCES RESPONSE AGAINST TYROSINE KINASE INHIBITORS IN PRECLINICAL MODELS OF MYELOID LEUKAEMIA
    Maria, Linares
    Maria Luz, Morales
    Alicia, Arenas
    Ivana, Zagorac
    Rosa Maria, Ayala
    Nerea, Castro
    Inmaculada, Rapado
    Miguel Angel, Quintela-Fandino
    Joaquin, Martinez-Lopez
    HAEMATOLOGICA, 2016, 101 : 175 - 175
  • [4] Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma
    Bridgeman, Victoria L.
    Wan, Elaine
    Foo, Shane
    Nathan, Mark R.
    Welti, Jonathan C.
    Frentzas, Sophia
    Vermeulen, Peter B.
    Preece, Natasha
    Springer, Caroline J.
    Powles, Thomas
    Nathan, Paul D.
    Larkin, James
    Gore, Martin
    Vasudev, Naveen S.
    Reynolds, Andrew R.
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (01) : 172 - 183
  • [5] MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia
    María Luz Morales
    Alicia Arenas
    Alejandra Ortiz-Ruiz
    Alejandra Leivas
    Inmaculada Rapado
    Alba Rodríguez-García
    Nerea Castro
    Ivana Zagorac
    Miguel Quintela-Fandino
    Gonzalo Gómez-López
    Miguel Gallardo
    Rosa Ayala
    María Linares
    Joaquín Martínez-López
    Scientific Reports, 9
  • [6] MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia
    Luz Morales, Maria
    Arenas, Alicia
    Ortiz-Ruiz, Alejandra
    Leivas, Alejandra
    Rapado, Inmaculada
    Rodriguez-Garcia, Alba
    Castro, Nerea
    Zagorac, Ivana
    Quintela-Fandino, Miguel
    Gomez-Lopez, Gonzalo
    Gallardo, Miguel
    Ayala, Rosa
    Linares, Maria
    Martinez-Lopez, Joaquin
    SCIENTIFIC REPORTS, 2019, 9 (1) : 18630
  • [7] Not Only Response but Early Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (03) : 223 - 224
  • [8] Tyrosine kinase inhibitors in chronic myeloid leukemia
    Sawyers, CL
    Druker, B
    CANCER JOURNAL FROM SCIENTIFIC AMERICAN, 1999, 5 (02): : 63 - 69
  • [9] Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations
    Abruzzese, Elisabetta
    Mauro, Michael
    Apperley, Jane
    Chelysheva, Ekaterina
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [10] Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia
    Bartaula-Brevik, Sushma
    Brattas, Marte Karen Lindstad
    Tvedt, Tor Henrik Anderson
    Reikvam, Hakon
    Bruserud, Oystein
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (04) : 377 - 387
12345